Literature DB >> 18224680

Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6.

Ryo Ueda1, Eiko Kinoshita, Rena Ito, Takeshi Kawase, Yutaka Kawakami, Masahiro Toda.   

Abstract

We previously reported identifying SOX6 as a glioma antigen by serological screening using a testis cDNA library. Its preferential expression and frequent IgG responses in glioma patients indicate that SOX6 may be a useful target for immunotherapy. To examine whether cytotoxic T-lymphocyte (CTL) responses specific for SOX6 to destroy glioma can be generated in vivo, we treated glioma-bearing mice by vaccination with a plasmid DNA encoding murine full-length SOX6 protein. Following SOX6-DNA vaccination, CTLs specific for SOX6-expressing glioma cells were induced, while normal autologous-cells that had restrictedly expressed SOX6 during embryogenesis were not destroyed. Furthermore, DNA vaccination with SOX6 exerted protective and therapeutic antitumor responses in the glioma-bearing mice. This antitumor activity was abrogated by the depletion of CD4 positive T cells and/or CD8 positive T cells. These results suggest that the SOX6 protein has multiple CTL and helper epitopes to induce antitumor activity and the effectiveness of SOX6-DNA vaccine for the prevention and treatment of glioma. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18224680     DOI: 10.1002/ijc.23366

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.

Authors:  Ryo Ueda; Mitsugu Fujita; Xinmei Zhu; Kotaro Sasaki; Edward R Kastenhuber; Gary Kohanbash; Heather A McDonald; Jay Harper; Scott Lonning; Hideho Okada
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

Review 2.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

3.  CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles.

Authors:  Kalle Andreasson; Mathilda Eriksson; Karin Tegerstedt; Torbjörn Ramqvist; Tina Dalianis
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

4.  The circRNA_102911/miR-129-5p/SOX6 axis is involved with T lymphocyte immune function in elderly patients with laparoscopic left hepatectomy for hepatolithiasis.

Authors:  Hongqiang Zhao; Xiaoyu Shao; Haorun Liu; Qi Liu; Jiangyang Lu; Weimin Li
Journal:  Exp Ther Med       Date:  2020-12-17       Impact factor: 2.447

Review 5.  Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy.

Authors:  Xiangyuan Luo; Xiaoyu Ji; Meng Xie; Tongyue Zhang; Yijun Wang; Mengyu Sun; Wenjie Huang; Limin Xia
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

6.  Improvement of cancer immunotherapy by combining molecular targeted therapy.

Authors:  Yutaka Kawakami; Tomonori Yaguchi; Hidetoshi Sumimoto; Chie Kudo-Saito; Tomoko Iwata-Kajihara; Shoko Nakamura; Takahiro Tsujikawa; Jeong Hoon Park; Boryana K Popivanova; Junichiro Miyazaki; Naoshi Kawamura
Journal:  Front Oncol       Date:  2013-05-28       Impact factor: 6.244

7.  Expression of cancer/testis antigens is correlated with improved survival in glioblastoma.

Authors:  Marcelo Freitas; Suzana Malheiros; João Norberto Stávale; Thais Priscila Biassi; Fernando Tadeu Zamunér; Maria de Souza Begnami; Fernando Augusto Soares; Andre Luíz Vettore
Journal:  Oncotarget       Date:  2013-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.